异麦芽糖酐铁治疗维持性血液透析患者缺铁性贫血的临床疗效分析

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (2343 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effificacy of Isomaltoside Iron in patients with maintenance hemodialysis (MHD) combined with iron defificiency anaemia (IDA). Methods 61patients with MDH combined with IDA in our hospital's blood purification center from June 2021 to June 2022 were selected and divided into sucrose iron group (29 cases) and isomaltoside iron group (32 cases) according to different treatment drugs. Patients in the sucrose iron group were treated with Sucrose Iron, while those in the isomaltoside iron group were treated with Isomaltoside Iron. After 3 months of continuous treatment, the changes in biochemical indicators (urea nitrogen, creatinine, PTH, hemoglobin, ferritin, transferrin saturation) and adverse reaction were compared between the two groups. Results Before treatment, there was no statistically significant difference between the clinical indicators of the two groups. After 3 months of treatment, there was no statistically significant difference in serum BUN, Scr, UA and PTH between the two groups. both the two groups had an increase in hemoglobin、ferritin and transferrin saturation levels, and the isomaltoside iron Group increased more significantly than sucrose iron group, which was statistically significant. At the same time, There is no statistically significant difference in the incidence of adverse events between the two groups of patients. Conclusion Compared with sucrose iron, isomaltoside iron induced a non-inferior haematological response, comparably low rates of hypersensitivity reactions, and exhibits faster effects, without increasing the incidence of adverse reactions。

Key words： hemodialysis isomaltoside iron sucrose iron iron-deficiency anemia

Received: 21 September 2023

PACS:

R692.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Yafen
	WU Rong

Cite this article:

JIANG Yafen,WU Rong. Analysis of clinical efficacy of Isomaltoside iron in patients with maintenance hemodialysis combined with iron defificiency anaemia[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(2): 124-126.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I2/124

[1] FERNADO V, HORLWALTER H, LAIN C M, et al.PRE-dialysis survey on anaemia management[J]. Nephrol Dial Transplant, 2003, 18(1): 89-100.
[2] ABOMHYA A, TAI W, AYAZ S, et al.Iron deficiency anemia: an overlooked complication of Crohn's disease[J]. J Hematol, 2022, 11(2): 55-61.
[3] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识 (2018修订版)[J]. 中华肾脏病杂志, 2018, 34(11): 860-866.
[4] 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
[5] 中华医学会血液学分会红细胞疾病盆血学组. 静脉铁剂应用中国专家共识 (2019 年版)[J]. 中华血液学杂志, 2019, 40(5): 358-362.
[6] 解玥, 张昭. 异麦芽糖酐铁、蔗糖铁和低分子右旋糖酐铁的临床价值比较[J]. 临床药物治疗杂志, 2021, 19(8): 29-33.
[7] 闫嘉, 赖学莉, 郭志勇. 静脉铁剂在腹膜透析患者中的应用[J]. 中国中西医结合肾病杂志, 2021, 22(6): 554-557.
[8] 王方海, 赵维, 陈建芳, 等. 补铁剂研究进展[J]. 药学进展, 2016, 40(9): 680-688.
[9] CREWS D C, BELLO A K, SAADI G, et al.Burden, access, and disparities in kidney disease[J]. Journal of Nephrology, 2019, 32(1): 1-8.
[10] ENE-LORDACHE B, PERICO N, BIKBOV B, et al.Chronic kidney disease and cardiovascular risk in xis regions of the world (ISN-KDDC): a cross-sectional study[J]. Lancet Glob Health, 2016, 4(5): 307-319.
[11] ZHANG L, WANG F, WANG L, et al.Prevalence of chronic kidney disease in China: a cross-sectional study[J]. Lancet, 2012, 379(9818): 815-822.
[12] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治智囊[J]. 中国实用内科杂志, 2017, 37(1): 28-34.
[13] LIU J, ZHANG H, DIAO Z, et al.Epidemiological analysis of death among patients on maintenance hemodialysis: results from the beijing blood purification quality Control and Improvement Center[J]. BMC Nephrology, 2023, 24: 236.
[14] MACGINLEY R, WALKER R, IRVING M.KHA CARI Guideline: use of iron in chronic kidney disease patients[J]. Nephrology (Carlton), 2013, 18(12): 747-749.
[15] HSU CY, MCCULLOCH CE, CURHAN GC.Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey[J]. J Am Soc Nephrol, 2002, 13(2): 504-510.
[16] IO H, AIZAWA M, FUNABIKI K, et al.Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents[J]. Nephrology (Carlton), 2015, 20(Suppl 4): 7-13.
[17] JESUS-SILVA JA, LAMPLUGH A, DHADA S, et al.Conversion of haemodialysis patients from iron sucrose to iron isomaltoside; a real -world experience[J]. BMC Nephrology, 2020, 21(1): 212.
[18] SUNIL B, KALRA P A, MARIO B, et al.Safety and efficacy ofiron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized. Ope-label, comparative trial[J]. Nephrol Dial Transplant, 2021, 36(1): 111-120.
[19] ZUO Q, WANG T, ZHU L, et al.A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients[J]. Ren Fail, 2022, 44(1): 94-102.
[20] 高伟祺, 徐娜, 宋再伟, 等. 新型静脉铁剂的安全性: 一项系统评价再评价[J]. 临床药物治疗杂志, 2022, 20(12): 7-12.